Understand the source comparison
Best VIP for Mold Illness: Research Grade Comparison
Choosing VIP for mold illness research requires evaluating synthesis method, purity verification, and supplier quality standards. The table below compares key specifications that affect research reproducibility and peptide bioactivity. Synthesis Method Solid-p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing VIP for mold illness research requires evaluating synthesis method, purity verification, and supplier quality standards. The table below compares key specifications that affect research reproducibility and peptide bioactivity.
- Synthesis Method
- Solid-phase peptide synthesis (SPPS) with automated coupling
- SPPS with manual verification
- Solution-phase synthesis or mixed methods
- SPPS automation reduces deletion sequences by 60–80% versus manual methods
- Purity by HPLC
- ≥98%
- 90–95%
- 85–90%
- Every 1% purity reduction introduces 200–400 mcg deletion sequences per 10 mg batch
- Amino Acid Sequencing Verification
- Mass spectrometry + Edman degradation
- Mass spectrometry only
- Certificate of analysis (no independent verification)
- Dual verification catches stereoisomer contamination mass spec alone misses
- Lyophilisation Standard
- Pharmaceutical-grade with cryoprotectant
- Standard freeze-dry
- Variable (often inadequate moisture control)
- Proper lyophilisation extends −20°C shelf life from 12 months to 36 months
- Storage Temp (Pre-Reconstitution)
- −20°C ± 2°C
- −20°C (range not specified)
- 2–8°C refrigeration
- Storage above −15°C accelerates degradation 5–8× versus proper freezing
- Reconstituted Stability (2–8°C)
- 21 days (with bacteriostatic water)
- 14 days
- 7 days or unspecified
- Stability correlates directly with initial purity and lyophilisation quality
- Typical Cost per 2 mg Vial
- Research pricing varies by volume
- 20–30% lower than pharmaceutical-grade
- 40–60% lower than pharmaceutical-grade
- Cost reduction below 30% threshold usually indicates purity or synthesis compromise
- Pharmaceutical-grade VIP sourced from suppliers with third-party verification and small-batch synthesis represents the gold standard for CIRS research. The purity difference between 98% and 92% VIP translates to 800 mcg of contaminating peptide fragments per 10 mg—enough to introduce competitive receptor antagonism that skews cytokine assay results and reduces reproducibility across study cohorts. Real Peptides supplies VIP synthesized under these exact pharmaceutical standards, with every batch undergoing mass spectrometry verification before release.